Ivacaftor (trade name Kalydeco, developed as VX-770) is a drug used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, who account for 4–5% cases of cystic fibrosis, and is included in a combination drug, lumacaftor/ivacaftor, which is used to treat people with cystic fibrosis who have the F508del mutation in CFTR.

CAS：873054-44-5
中文别名：
英文别名：UNII-1Y740ILL1Z;VX770,VX 770,Ivacaftor;N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide;N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide;Ivacaftor;N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide;[14C]-Ivacaftor;N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxaraide;Ivacaftor (VX-770);N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide;Kalydeco;VX770;
分子式：C24H28N2O3
分子量：392.491
精确质量：392.21
Psa：85.68
Logp：5.465

MDL号：MFCD17171361

密度：1.187 g/cm3
沸点：550.4ºC at 760 mmHg
闪点：286.7ºC